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Dermal tissue remodeling and non-osmotic 
sodium storage in kidney patients
Ryanne S. Hijmans1,2,3*, Marco van Londen1, Kwaku A. Sarpong1, Stephan J. L. Bakker1, Gerjan J. Navis1, 
Twan T. R. Storteboom4, Wilhelmina H. A. de Jong4, Robert A. Pol2 and Jacob van den Born1
Abstract 
Background: Excess dietary sodium is not only excreted by the kidneys, but can also be stored by non-osmotic bind-
ing with glycosaminoglycans in dermal connective tissue. Such storage has been associated with dermal inflamma-
tion and lymphangiogenesis. We aim to investigate if skin storage of sodium is increased in kidney patients and if this 
storage is associated with clinical parameters of sodium homeostasis and dermal tissue remodeling.
Methods: Abdominal skin tissue of 12 kidney patients (5 on hemodialysis) and 12 healthy kidney donors was 
obtained during surgery. Skin biopsies were processed for dermal sodium measurement by atomic absorption spec-
troscopy, and evaluated for  CD68+ macrophages,  CD3+ T-cells, collagen I, podoplanin + lymph vessels, and glycosami-
noglycans by qRT-PCR and immunohistochemistry.
Results: Dermal sodium content of kidney patients did not differ from healthy individuals, but was inversely associ-
ated with plasma sodium values (p < 0.05). Compared to controls, kidney patients showed dermal tissue remodeling 
by increased  CD68+ macrophages,  CD3+ T-cells and Collagen I expression (all p < 0.05). Also, both N- and O-sulfation 
of heparan sulfate glycosaminoglycans were increased (all p < 0.05), most outspoken in hemodialysis patients. Plasma 
and urinary sodium associates with dermal lymph vessel number (both p < 0.05), whereas loss of eGFR, proteinuria 
and high systolic blood pressure associated with dermal macrophage density (all p < 0.05).
Conclusion: Kidney patients did not show increased skin sodium storage compared to healthy individuals. Results 
do indicate that kidney failure associates with dermal inflammation, whereas increased sodium excretion and plasma 
sodium associate with dermal lymph vessel formation and loss of dermal sodium storage capacity.
Trial registration The cohort is registered at clinicaltrials.gov as NCT (September 6, 2017). NCT, NCT03272841. Regis-
tered 6 September 2017—Retrospectively registered, https ://clini caltr ials.gov
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Background
Over the past decades, the classical paradigm of sodium 
handling by the human body has been widely questioned 
[1–3]. New evidence suggests that besides via regulation 
of sodium excretion by the kidneys, sodium can also be 
stored in a non-osmotic manner in bone, cartilage and 
skin tissue [2, 4]. Especially skin has been shown to func-
tion as an extra compartment for sodium storage [5].
In a previous animal study, we showed increased der-
mal sodium concentrations in rats who received a high 
sodium diet for 4  weeks [6]. However, human dermal 
tissue remodeling responses such as lymphangiogenesis, 
fibrosis and inflammation have not been investigated, 
especially not in relation to dermal sodium concentra-
tions. A recent study showed that the sodium storage 
in human tissues, such as arteries, skin and muscle, is 
mediated by glycosaminoglycans (GAGs) [7]. While it 
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synthesis of GAGs, is increased, that study did not inves-
tigate in greater detail, which GAGs are involved.
In previous studies, our group showed that upon 
various noxi, renal proteoglycans and their covalently 
attached GAG side chains (such as heparan sulfate, 
HS) can be converted into pro-inflammatory media-
tors orchestrating macrophage influx, T-cell influx, and 
contribute to fibrosis and lymphangiogenesis [6, 8]. Our 
studies, among others, have shown that this conversion 
can also be induced by a high sodium diet [6, 9–11].
In order to investigate these phenomena, we focused 
on the growing group of patients with end stage renal dis-
ease (ESRD) and who were in need of renal replacement 
therapy (RRT) [12]. These patients are suffering from 
CKD and are matched up with healthy renal transplant 
donors. While early transplantation (CKD above stage 5; 
preemptive) has several benefits in terms of patient and 
grafts survival [13, 14], the majority of patients suffer-
ing from ESRD are dialysis dependent and awaiting renal 
transplantation. Multiple studies have shown high car-
diovascular morbidity and mortality in dialysis patients, 
mainly associated by systemic inflammation which can 
be induced by uremia, the underlying renal disease, dialy-
sis-related factors and comorbidities [15–17].
In order to decrease cardiovascular morbidity and 
mortality, the driving forces of systemic inflammation in 
patients with chronic kidney disease, and especially in 
dialysis patients, need further investigation.
In this study, we aim to investigate whether skin stor-
age of sodium is increased in kidney patients (i.e. both 
hemodialysis patients and preemptive patients), compar-
ing them to healthy individuals (kidney donors). Second, 
we hypothesize that skin storage of sodium is associated 
with clinical parameters of sodium homeostasis, such as 
plasma sodium regulation and sodium excretion. Next, 
we hypothesize that dermal sodium storage is associ-
ated with tissue remodeling responses such as changes in 
GAGs, inflammation, lymphangiogenesis and fibrosis.
Methods
Study population
For this study, full thickness skin biopsies were obtained 
from 12 healthy controls (kidney donors) and 12 kidney 
patients at the time of renal transplantation (recipients), 
undergoing surgery at the University Medical Center 
Groningen (UMCG) between 14th February and 22nd 
March 2017. Of the 12 kidney patients, 5 were on hemo-
dialysis (HD). From all patients, blood and urine were 
analyzed for sodium (Ion Selective Electrode by Roche 
Modular, Roche, Mannheim, Germany) and creatinine 
concentration (Roche Modular Enzymatic method, 
Roche, Mannheim, Germany). For all renal patients, clin-
ical data were obtained from electronic patient files and 
the urine and plasma were collected on the day of the 
operation (OR) or 1 day before the OR. For the healthy 
donors, clinical data were also obtained from their elec-
tronic files. Urine and plasma were collected 1 day before 
OR or a week before OR. All study participants provided 
written informed consent prior to study and are enrolled 
in the Transplantlines Biobank and Cohort study 
(TXLINES01). The cohort is registered at  clinicaltrials.
gov as NCT03272841.
The study protocol is in accordance with the Dutch 
Medical Research Involving Human Subjects Act 
(WMO), and approved by the Medical Ethics Commit-
tee of the University Medical Center Groningen (METc 
2014/077). All procedures were conducted in accordance 
with the declarations of Helsinki and Istanbul.
Study protocol
Pre-operatively, both kidney donors and kidney patients 
received intravenous antibiotic profylaxis (2 g Cefalozlin 
and 500 mg Metronidazole) 30 min prior to the OR. Next 
to this all patients received 200  mL of intravenous 15% 
Mannitol at the time of induction. Renal patients (recipi-
ents) also received intravenous immunosuppressive 
medication pre-OR (40  mg  Solumedrol®, 0.075  mg/kg 
Tacrolimus, 2000 mg  Cellcept® and 20 mg Basiliximab). 
In case of identical HLA-typing, the Basiliximab was 
not given. All patients who were on dialysis received HD 
1  day before surgery. One of the patients received plas-
mapheresis the day before the OR for immuno-absorp-
tion because of ABO-incompatibility. Of the 5 patients 
on hemodialysis, 1 received ultrafiltration to 1 kg above 
goal weight during the last dialysis. Abdominal full-thick-
ness skin tissue was obtained from kidney donors and 
kidney patients during transplant surgery after incision. 
Immediately after skin biopsies were taken under dry 
and sterile conditions, they were placed in a tin container 
kept cool on ice (0  °C) with the precaution of avoiding 
any contact of the skin with water or saline. The skin 
samples were then transported to the research laboratory 
for processing. There, the skin tissue was pinned on a 
sterile, flat surface and 1 or 2 biopsies (depending on size 
of harvested skin) were taken with a biopsy punch (Stie-
fel Biopsy Punch, 6  mm; SmithKline Beecham, UK) for 
immunohistochemistry. The remainder of the tissue was 
divided in halve and the halves were placed in two sterile 
Eppendorf tubes for future qPCR and sodium measure-
ments after which all processed skin samples were stored 
in a minus 80 °C freezer.
Measurement of dermal sodium
The skin samples for determination of sodium content 
were cut into two equal parts and wet weights were 
measured. Both halves were then dried overnight in an 
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oven at 80 °C after which their dry weight was measured. 
One of the samples was then dissolved in a destruction 
solution made up of a 4:1 mixture of perchloric acid and 
pure nitric acid (Sigma-Aldrich, St Louis, USA) at 60 °C 
for 3 h. To 0.5 mL sample solution, 4.5 mL of water was 
added to obtain a 5 mL stock sample solution. The sample 
solution was then diluted 1:1000 after which the sodium 
content was measured by atomic absorption (flame) 
spectrometry using the Thermo M Series AA Spectrom-
eter (Thermo Fisher Scientific, Waltham, USA). The sec-
ond half of the sample was used to calculate the amount 
of protein per sample by measuring the nitrogen content 
using a Dumas method (Dumatherm Nitrogen/Protein 
analyser, C. Gerhardt UK Ltd, Northamptonshire, UK). 
Sodium concentrations were expressed as µmol sodium 
per mg protein.
Immunohistochemistry
Immunohistochemical staining was performed on 
4-μm-thick cryo sections cut from skin biopsies with 
a Leica CM1950 cryostat (Leica Biosystems, Wetzlar, 
Germany) followed by acetone or 4% paraformaldehyde 
fixation for 10 min. Endogenous peroxidase activity was 
blocked by incubating with 0.03% hydrogen peroxide (in 
phosphate buffered saline; PBS). Endogenous biotin bind-
ing sites were blocked by an Avidin/Biotin blocking step 
in case of biotin-labeled reagents. Skin cryo sections were 
incubated for 1  h with the following primary antibod-
ies/reagents: mouse anti-human α-smooth muscle actin 
(SMA; clone 1A4, Sigma-Aldrich, St Louis, USA), rabbit 
anti-human CD3 (clone A0452, Dako, Glostrup, Den-
mark), biotinylated hyaluronan binding protein (HABP, 
Seikagaku, Tokyo, Japan), mouse anti heparan sulphate 
mAB JM403 [18], mouse anti-human podoplanin (Clone 
D240, ThermoFisher, Rockford, USA), mouse anti-human 
CD68 (clone ED1, AbD Serotec, Oxford, UK), rabbit anti-
versican (ITK Diagnostics, B.V., Uithoorn, The Nether-
lands) and mouse anti-human MCP-1 (Peprotech, Rocky 
Hill, USA) diluted in PBS/1% Bovine Serum Albumin 
(BSA). Binding of primary antibodies was detected by 
incubating the sections for 30 min with either a second-
ary or both secondary and tertiary antibodies diluted 
in PBS/1% BSA (and 1% normal human serum in some 
cases). We used rabbit anti-mouse Ig horseradish peroxi-
dase (HRP), goat anti-rabbit Ig HRP, goat anti-mouse Ig 
HRP, rabbit anti-goat Ig HRP, (all from Dako, Heverlee, 
Belgium) in PBS/1% BSA. As negative controls, the pri-
mary antibodies were replaced by PBS/1% BSA and were 
all found to be negative. Bound antibodies were visual-
ized by aminoethylcarbazole (AEC) counterstained with 
diluted hematoxylin or by the TSA TM tetramethylrho-
damine system (PerkinElmer Life Sciences Inc., Waltham, 
USA) (10 min) for HRP antibodies. In the detection of 
CD3 antigen immunoreactivity was visualized using 
3,3′-diaminobenzidine (DAB) solution. Biotinylated 
HABP was visualized using Cy3 conjugated streptavidin 
(Invitrogen, Carlsbad, USA). DAPI solution (Vector labo-
ratories, Burlingame, USA) was applied to the sections 
and incubated for 10  min for nuclear staining and sub-
sequently mounted in either Citifluor mounting medium 
(fluorescence) or Aquatex mounting medium. The whole 
staining procedure was carried out at room temperature.
Quantification of immunohistochemistry
Stainings were evaluated on a Leica DM4000B (Leica 
Biosystems Wetzlar, Germany) equipped for immuno-
fluorescence, and with a DFX345FX camera using a LAS 
software package. At least 5 pictures at 20 × magnifica-
tion per skin sample were taken followed by digital quan-
tification using ImageJ 1.46r (Rasband, W.S., US National 
Institutes of Health) and expressed as % positively stained 
area (for macrophages, glycosaminoglycans and collagen 
I). D2-40 podoplanin positive lymphvessles and CD3-
positive T-cells were quantified manually by two inde-
pendent researchers and the mean of both scorings were 
used, expressed per standardized tissue area.
Gene expression
RNA was isolated from frozen skin tissue by the Favor-
Prep Tissue Total RNA Mini Kit (Favorgen Biotech 
Corp, Vienna, Austria) according to the manufacturer’s 
protocol. The total amount of RNA after isolation was 
measured by a nanodrop UV-spectrometer (Nanodrop 
Technologies, Wilminton, DE, USA) at 260/280 nm.
From 700  ng RNA, cDNA was synthesized using the 
Quantitect reverse transcription kit (Qiagen, Venlo, the 
Netherlands) in accordance with the manufacturer’s 
protocol. The following solutions were added to 1  ng/
µL RNA: 2 µL genomic DNA wipeout buffer, 1 µL Quan-
tiscript Reverse Transcriptase (RT), 4  µL 5× RT Buffer, 
1 µL RT Primer Mix and RNase-free water (up to 20 µL). 
The samples were placed in a MyCycler™ Thermal Cycler 
(Bio-Rad Laboratories) to start the cDNA synthesis with 
1 cycle of 42 °C/15 min and 95 °C/3 min. Afterwards, the 
cDNA samples were diluted with 130 µL of RNAse-free 
water and stored at 4  °C (for use shortly). For quantita-
tive reverse transcription-polymerase chain reaction 
(qRT-PCR), 3  µL cDNA (diluted 3× from stock) and 
7 µL SYBR Green-Primer- Water mix (consisting of 5 µL 
SYBR Green Supermix (BioRad, Veenendaal, The Neth-
erlands), 0.08 µL gene specific primer set (0.5 mM) and 
1.92  µL MilliQ water) were pipetted into a 384 wells 
plate (Applied Biosystems, Foster City, CA). All reac-
tions were performed in triplicate. The plate was covered 
with an adhesive cover and centrifuged for 30  s. Prim-
ers were ordered from Sigma and the sequences of the 
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oligonucleotides are shown in Table 1 below. Amplifica-
tion was performed using an ABI7900HT Thermal cycler 
(Applied Biosystems) with the cycle procedure as follows: 
10 min at 95  °C, with 40 repeats of a 15  s denaturation 
step at 95 °C and a 40 s extension and annealing step at 
60 °C. Data analysis was performed using science detec-
tion software 2.4 (Applied Biosystems). To determine dif-
ferences in expression of gene of interest, Ct-values were 
normalized against mean Ct-values of β-Actin as house-
keeping gene.
Statistics
Data are shown as median (interquartile range) and com-
parisons between groups were performed by Mann–
Whitney U test. Spearman Rank correlation coefficient 
on the Z-scores of various parameters was used for asso-
ciation studies. Statistical analysis were performed using 
SPSS 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad 
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) 
was used to construct graphs and figures. P values below 
0.05 were considered statistically significant.
Results
Clinical characteristics
Descriptive data are given for healthy individuals (donors, 
n = 12) and kidney patients (recipients, n = 12) in Table 2. 
The kidney patients in this study were younger compared 
to the healthy donors (p = 0.05), and there were more 
male recipients compared to male donors (although not 
significantly different, p = 0.23). Healthy individuals and 
kidney patients in this study are well matched for length 
(p = 0.05) and weight (p = 0.78). Blood pressure did not 
significantly differ between the two groups (systolic 
p = 0.23 and diastolic p = 0.25). Kidney patients suffered 
from various renal diseases and had more comorbidity, 
such as hypertension, coronary heart disease and diabe-
tes mellitus. Therefore, they also used more anti-hyper-
tensive, diuretic and anti-diabetic medication. In terms 
of kidney function eGFR (p < 0.001), plasma sodium 
(p = 0.006) and urine sodium (p = 0.02) were significantly 
decreased in kidney patients compared to healthy indi-
viduals, while proteinuria was significantly higher in kid-
ney patients compared to the healthy donors (p = 0.001).
No significant differences were found between kid-
ney patients who were on dialysis (n = 5) and patients 
in higher CKD stages (preemptive, n = 7) for the clinical 
characteristics. Compared to healthy controls, there were 
no significant differences in age, sex, length, weight and 
blood pressure (Table 2, right column). The median time 
on dialysis prior to renal transplantation was 13 (8–18) 
months. Twenty percent of the dialysis patients had been 
on peritoneal dialysis prior to hemodialysis. There was 
Table 1 Primer oligonucleotide sequences (forward and reverse) used in RT-qPCR
Primer Forward sequence Reverse sequence
A. Inflammation
 CCL2 5′-AGA CTA ACC CAG AAA CAT CC-3′ 5′-ATT GAT TGC ATC TGG CTG -3′
 VCAM 5′-TCC TGA GCT TCT CGT GCT CTATT-3′ 5′-TGA CCC CTT CAT GTT GGC TT-3′
B. Fibrosis
 COL1A1 5′-GGG ATT CCC TGG ACC TAA AG-3′ 5′-GGA ACA CCT CGC TCT CCA -3′
C. Lymphangiogenesis
 VEGFC 5′-CTG GCT CAG GAA GAT TTT ATG-3′ 5′-TGT TTT TAC AGA CAC ACT GG-3′
 PDPN 5′-AAG ATG GTT TGT CAA CAG TG-3′ 5′-GTA CCT TCC CGA CAT TTT TC-3′
D. Proteoglycan related
 VCAN 5′-CCA GTG TGA ACT TGA TTT TG-3′ 5′-CAA CAT AAC TTG GAA GGC AG-3′
 NDST1 5′-CGT GAC GCG ACC TAG CGA -3′ 5′-TCA TAG GTG GAG TGA TTT GAC TGG -3′
 HS6ST1 5′-AGG AAG TTC TAC TAA CAT CACC-3 5′-CCC ATC ACA CAT ATG CAA C-3′
 HSPE 5′-CCT TGC TAT CCG ACA CCT TT-3′ 5′-GGC TGA CAG GCC CAA TTT A -3′
 CHYSY1 5′-AGA CTT TCA GCA AAA TCC AG-3′ 5′-GTT TGA GAG AAA GGA CAA GG-3′
 HAS1 5′-TCC ACT GTG TAT CCT GCA TC-3′ 5′-CCC CAA AAG TAT CCT GCA TC -3′
 HAS2 5′-GAT GCA TTG TGA GAG GTT TC-3′ 5′-CCG TTT GGA TAA ACT GGT AG-3′
 HAS3 5′-CTT GAA GAT TAA TGT AGG ATG ACA GGCT-3′ 5′-AAA GTT GAC GAC CAC AGT GCAA-3′
 UST 5′-GAA CGT GAA TGA AAA CTT CC-3′ 5′-TCT GGG TCT TTG TAG ATA CTG-3′
 CHST11 5′-TAT TTC CAA ATC ATG CGG AG-3′ 5′-ATT GGG TTG TAG AGT TCC TG-3′
E. Housekeeping
 β-Actin 5′-CCA ACC GCG AGA AGA TGA -3′ 5′-CCA GAG GCG TAC AGG GAT AG-3′
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no significant difference in drug use between the groups, 
but the groups did show significant differences compared 
to the healthy individuals. While both groups showed 
a significantly lower eGFR compared to the eGFR val-
ues in the healthy controls (preemptive; p < 0.001, dialy-
sis; p = 0.009), and significantly higher serum creatinine 
Table 2 Baseline characteristics between healthy individuals (donors) and kidney transplant recipients
* Significantly different compared to healthy donors (* p < 0.05, ** p < 0.01, *** p < 0.001)
Variables Healthy individuals 
donors (N = 12)
Renal patients recipients (N = 12)
All Preemptive Dialysis
(N = 12) (N = 7) (N = 5)
Age (years) 61 [53–67] 52 [43–60]* 51 [48–64] 53 [41–60]
Sex (% male) 33 58 57 60
Length (cm) 166 [161–178] 176 [170–183] 176 [170–182] 175 [168–184]
Weight (kg) 81 [73–91] 77 [70–87] 73 [70–82] 84 [73–94]
BMI (kg/m2) 29 [25–31] 24 [22–28] 24 [22–25]* 26 [23–32]
Blood pressure (mmHg)
 Systolic 138 [129–150] 150 [131–158] 151 [122–165] 149 [136–152]
 Diastolic 80 [72–85] 87 [71–95] 88 [69–98] 86 [63–89]
Time on dialysis, months – – – 13 [8–18]
Dialysis (%)
 Hemodialysis – – – 80
 First peritoneal, switched to hemodialysis – – – 20
Underlying disease (%)
 Healthy donor 100 0 0 0
 IgA Nephropathy 0 17 14 20
 Focal Segmental 0 17 14 20
Glomerulo-sclerosis
 ADPKD 0 33 29 40
 Glomerulonephritis 0 25 29 20
 Other 0 8 14 0
Known comorbidities (%)
 Hypertension 8 67 58 80
 Malignancy 8 8 14 0
 Coronary heart disease 8 17 14 20
 Diabetes mellitus 0 8 0 20
 Other 8 17 14 40
 No relevant comorbidities 67 17 29 0
Drug use (%)
 Anti-hypertensives 42 67 86 40
 Diuretics 0 42* 43* 40*
 Anti-diabetics 0 8 0 20
Dermal sodium content (µmol/mg protein) 0.68 [0.45–0.94] (n = 8) 0.89 [0.59–1.01] (n = 11) 0.98 [0.59–1.12] (n = 7) 0.83 [0.45–0.89] (n = 4)
Laboratory characteristics (day of OR)
 eGFR (mL/min) 91 [81–95] 11 [8–14] *** 11 [10–14]*** 8 [6-X]** (n = 3)
 Serum creatinine (umol/L) 68 [63–84] 514 [447–646]*** 462 [442–516]*** 619 [399–1065]**
 Serum albumin (mmol/L) 44 [43–46] 43 [41–46] 43 [42–50] 42 [40–45]
 Plasma sodium (mmol/L) 141 (140–143] 43 [41–46] 139 [138–142] 137 [137–140]**
 Urine creatinine (mmol/L) 6.5 [4.2–11.9] 6.4 [3.8–8.9] 5.4 [3.2–8.2] 8.6 [6.4–13.1]
 Proteinuria (g/L) 0.04 [0.03–0.06] 1.92 [0.26–2.35]** 0.39 [0.26–6.60]** 2.09 [0.54–2.33]**
 Urine sodium (mmol/L) 85 [60–119] 62 [41–68]* 62 [56–68] 44 [22–77]
 Sodium excretion (mmol/24 h) 128 [20–192] 107 [40–140] 116 [54–166] 107 [17–X] (n = 3)
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(preemptive; p < 0.001, dialysis; p = 0.002) and proteinuria 
(preemptive; p = 0.003, dialysis; p = 0.008), only the dialy-
sis group showed significantly lower plasma sodium lev-
els compared to the healthy individuals (p = 0.006).
Dermal sodium and sodium homeostasis
Plasma sodium was higher in healthy donors compared 
to kidney patients (p = 0.006), especially with hemodialy-
sis patients (p = 0.006). Urinary sodium excretion values 
did not significantly differ between donors and kidney 
patients (Fig.  1a, b, p = 0.77). The patients with CKD 
above stage 5 and the hemodialysis patients did not show 
any differences in sodium excretion (Fig. 1b, preemptive; 
p = 0.87, dialysis; p = 0.47). The dermal sodium concen-
tration was not significantly different between donors 
and kidney patients (p = 0.31). However, there were 
apparently slightly higher dermal sodium concentrations 
in the kidney patients, especially in the preemptive group 
(Fig. 1c).
Dermal tissue remodeling
Dermal tissue remodeling events such as inflammation, 
fibrosis and lymphangiogenesis are shown in Figs. 2, 3 
and 4. Dermal inflammation was evidenced by a signifi-
cantly increase of CD68 + macrophages throughout the 
dermal tissue in kidney patients compared to healthy 
donors (p = 0.01). Both the preemptive kidney patients 
and the hemodialysis patients showed significantly 
higher expression of macrophages compared to the 
healthy renal transplant donors (Fig.  2a, preemptive; 
p = 0.04, dialysis; p = 0.04). While monocyte chemoat-
tractant protein-1 (MCP-1) expression in the endothe-
lium of dermal blood vessels was apparently slightly 
higher throughout the dermal tissue in kidney patients 
compared to healthy individuals, especially in the 
preemptive group, this difference was not statistically 
significant (Fig. 2a, p = 0.29). The influx of  CD3+ T-cells 
also showed an apparent increase in kidney patients 
compared to healthy donors (p = 0.04). Hemodialy-
sis patients showed a significantly higher amount of 
T-cells compared to the healthy donors, preferentially 
peri-vascular (Fig. 2a, p = 0.03). The mRNA expression 
of MCP-1 did not show any significant differences with 
a broad variance in the donor group (Fig. 2b, p = 0.97). 
The expression of VCAM-1 also did not show any sig-
nificant differences (Fig.  2b, p = 0.09). The data indi-
cate that kidney disease is associated with an influx of 
macrophages and T-cells in the dermal layer of the skin, 
most outspoken in the hemodialysis patients.
Fibrotic changes in dermal tissue were not shown to 
be significantly different between healthy donors and 
kidney patients by immunohistochemical quantification 
of α-SMA + dermal myofibroblasts (Fig.  3a, p = 0.94). 
The mRNA expression of collagen I was higher in kid-
ney patients compared to the healthy individuals, but not 
statistically significant (Fig.  3b, p = 0.10). Hemodialysis 
patients, showed a significantly higher expression of col-
lagen I compared to preemptive (p = 0.02) and compared 
to the healthy donors (p = 0.001). Preemptive patients did 
not have an increased expression of collagen I compared 
to healthy donors (p = 0.81). Thus, patients with kidney 
disease show an increased dermal collagen I synthesis, 
most outspoken in the hemodialysis patients.
Kidney patients did not show significant differ-
ences in dermal lymph vessel number compared to 
healthy donors (p = 0.67), although the highest den-
sity was found in hemodialysis patients (Fig.  4a). Also 
mRNA expression of Podoplanin tended to be higher 
in kidney patients compared to healthy individuals 
(p = 0.14). Hemodialysis patients showed significantly 
higher mRNA expression of Podoplanin compared to 
preemptive (p = 0.05) and compared to healthy donors 
(p = 0.02). The mRNA expression of VEGF-C did not 
show any significant differences between healthy indi-
viduals and kidney patients due to the large variance 
(p = 0.79). However, a number of hemodialysis patients 
showed a higher VEGF-C expression compared to 
healthy donors and preemptive (Fig. 4b). The data sug-
gest increased dermal lymphangiogenesis in kidney 
patients, most outspoken in hemodialysis recipients.
Fig. 1 Plasma sodium (a), urinary sodium excretion (b) and dermal sodium concentration (c) in healthy individuals (donors) and kidney patients 
(recipients). Mann–Whitney and Kruskall Wallis were used to test differences between two or more groups. *p < 0.01
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Glycosaminoglycans
Differences in expression of GAGs were investigated 
for heparan sulfate (HS-GAG), chondroitin and derma-
tan sulfate (CS/DS-GAGs) and hyaluronic acid (HA-
GAG) (Fig.  5). JM403, a monoclonal antibody reacting 
to a low-sulfated epitope on HS-GAG, showed a slightly 
lower (non-significant) vascular and epidermal base-
ment membrane expression in kidney patients compared 
to healthy controls (Fig.  5a, p = 0.38). On mRNA level, 
N-deacetylase, N-sulfotransferase-1 (NDST1), which 
is responsible for the N-sulfation in HS-GAG, showed 
to be significantly higher in kidney patients compared 
to healthy individuals (p = 0.04) and dialysis patients in 
particular (Fig.  5b; p = 0.01) and is in line with loss of 
mAb JM403 stainability due to increased sulfation. No 
significant changes (p = 0.12) were found in heparan 
sulfate 6-O-sulfotransferase-1 (HS6OST1), which is the 
most important enzyme for HS-GAG 6-O sulfation, nei-
ther were significant differences found for HSPE, coding 
Fig. 2 Dermal inflammation in kidney patients (recipients) and healthy individuals (donors). Immunohistochemical expression and quantification 
of  CD68+ macrophages, MCP-1 and  CD3+ T-cells. Magnification ×200. a. The mRNA expression of MCP-1 and VCAM-1 by qRT-PCR analysis (b). Values 
are expressed in fold increase compared to the mean of the donors. Mann–Whitney and Kruskall Wallis were used to test differences between two 
or more groups. *p < 0.05 compared to donors
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for the HS-GAG degrading enzyme heparanase (Fig. 5b, 
p = 0.63).
For CS/DS-GAG, we evaluated versican, a dominant 
dermal CS/DS proteoglycan. The dermal expression of 
versican in the tissue did not show any difference between 
the groups (Fig. 5c, p = 0.83) and also on mRNA level, the 
expression of versican (p = 0.55) and the major enzymes 
involved in CS/DS synthesis and sulfation, namely the 
chondroitin 4-O-sulfotransferase-1 or carbohydrate sul-
fotransferase-11 (CHST11, p = 0.40), the chondroitin 
sulfate synthase 1 (CHSY1, p = 0.09) and dermatan/chon-
droitin sulfate 2-sulfotransferase or uronyl 2-sulfotrans-
ferase (UST, p = 0.13) did not differ (Fig. 5d). However, it 
was striking that the mRNA expression of versican and 
all CS/DS-GAG enzymes were apparently a bit higher in 
the dialysis group compared to the healthy controls and 
the preemptive.
Reduced dermal expression of HA-GAG was found 
in hemodialysis patients compared to healthy donors 
(Fig. 5e, p = 0.04). mRNA expression of hyaluronan syn-
thase 1, 2 and 3 (HAS1-3) did not show significant dif-
ferences between groups (Fig. 5f, HAS1; p = 0.18, HAS2; 
p = 0.32, HAS3; p = 0.10).
Association studies
The relationship between dermal sodium concentra-
tions, sodium homeostasis, tissue remodeling (inflam-
mation, fibrosis, lymphangiogenesis, and GAGs) and 
kidney function, was investigated by correlating these 
parameters in donors (n = 12) and preemptive recipients 
(n = 7) together as one group. Hemodialysis recipients 
were excluded from this analysis because the preopera-
tive dialysis might have influenced plasma and dermal 
sodium concentrations (see also Fig.  1a and c preemp-
tive patients versus hemodialysis recipients). Figure 6 and 
Table 3 show these correlations and their relation to each 
other.
Dermal sodium storage negatively correlated with 
the mRNA expression of CCL2, as a marker for inflam-
mation (Fig.  6; Table  3A; r = − 0.582; p = 0.02). Next to 
this, dermal sodium storage also correlated negatively 
with one of the markers of sodium homeostasis, namely 
plasma sodium (Fig.  6; Table  3B; r = − 0.619; p = 0.04). 
Sodium homeostasis, reflected by plasma sodium, and 
increased sodium intake, reflected by increased sodium 
excretion values, shows positive correlations with param-
eters for lymphangiogenesis (Fig.  6; Table  3C; r = 0.656; 
p = 0.03 and r = 0.709; p = 0.02, respectively). We did 
not find a correlation between dermal sodium and 
Fig. 3 Dermal fibrosis in kidney patients (recipients) and healthy individuals (donors). Immunohistochemical expression and quantification of 
α-SMA+ myofibroblasts. Magnification ×200. a. The mRNA expression of collagen I on qRT-PCR analysis (b). Values are expressed in fold increase 
compared to the mean of the donors. Mann–Whitney and Kruskall Wallis were used to test differences between two or more groups. *p < 0.05 and 
**p < 0.01 compared to donors
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lymphangiogenesis parameters (Fig.  6). Parameters for 
renal function such as proteinuria and loss of GFR were 
positively correlated with markers for inflammation 
(Fig. 6; Table 3D).
Age and body weight showed positive correlations with 
different GAGs (Fig.  6; Table  3). GAGs showed mostly 
positive correlations with parameters for lymphangi-
ogenesis, fibrosis and inflammation (Fig. 6; Table 3).
Discussion
In this study, we showed that dermal non-osmotic 
sodium storage is not increased in patients with chronic 
kidney disease, but that kidney disease plays a part in 
the interplay between dermal sodium storage, sodium 
homeostasis and dermal tissue remodeling. In the last 
decade, the classic paradigm of sodium handling has 
been questioned and widely investigated [2, 4, 19]. These 
studies have shown that extra-renal non-osmotic sodium 
storage in skin, cartilage and bone plays an important 
role in maintaining a balanced plasma sodium level. 
Our data indicate that sodium homeostasis reflected by 
plasma sodium and increased sodium intake reflected 
by increased sodium excretion, associates with dermal 
lymph vessel formation and loss of dermal sodium stor-
age capacity, whereas kidney failure associates with 
dermal inflammation. We also show that dialysis further 
influences dermal tissue remodeling.
In this current study, human dermal sodium concentra-
tions were determined by atomic absorption spectros-
copy. However, we did not find significant differences 
in dermal sodium concentration between healthy indi-
viduals and kidney patients. Plasma sodium levels were 
significantly lower in kidney patients on hemodialysis 
compared to the healthy donors. This suggests that the 
lower plasma sodium levels were the result of hemodialy-
sis prior to surgery. In a previous animal study in which 
rats received a high sodium diet during 4 weeks, we did 
show a significant increase in dermal sodium concen-
tration compared to controls on a normal diet using the 
same spectroscopy technique [6]. The fact that we were 
not able to show any significant differences during the 
current study might be explained by the fact that the 
donors and kidney patients were not on a high sodium 
diet in a controlled manner. Other research groups inves-
tigated sodium storage using a sodium-MRI technique in 
healthy volunteers, hypertensive patients and patients on 
hemodialysis [5, 20]. Such studies have shown increased 
dermal sodium storage in elderly, males, hypertensive 
patients and patients on hemodialysis [1, 20, 21]. Dahl-
mann et  al. showed that hemodialysis treatment is able 
Fig. 4 Dermal lymphangiogenesis in kidney patients (recipients) and healthy individuals (donors). Immunohistochemical expression and 
quantification of Podoplanin + lymph vessels. Magnification ×200. a The mRNA expression of Podoplanin and VEGF-C on qRT-PCR analysis (b). 
Values are expressed in fold increase compared to the mean of the donors. Mann–Whitney and Kruskall Wallis were used to test differences 
between two or more groups. *p < 0.05 compared to donors or compared to non-dialysis (preemptive) patients
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Fig. 5 Dermal GAGs in kidney patients (recipients) and healthy individuals (donors). Immunohistochemical expression and quantification of 
GAGs and versican and mRNA expression of enzymes involved in the synthesis of HS-GAG (a, b), CS/DS-GAG (c, d) and HA-GAG (e, f). Photos: 
magnification ×200. For qRT-PCR data, values are expressed in fold increase compared to the mean of the donors. Mann–Whitney and Kruskall 
Wallis were used to test differences between two or more groups. *p < 0.05
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to mobilize sodium and water from the non-osmotic 
storage sites (skin and muscle), therefore lowering the 
dermal sodium concentration in these patients. They 
suggest that by reducing the intravascular volume dur-
ing adequate hemodialysis, dermal sodium levels can be 
remained stable [21]. The dialysis patients in our study, 
received hemodialysis prior to the OR, which makes it 
possible that the non-osmotic sodium had been mobi-
lized already and therefore skin sodium concentrations 
returned to control values.
Focusing on tissue remodeling, inflammatory markers 
showed significant differences between the donors and 
the kidney patients. There was an influx of macrophages 
in both the skin tissue of preemptive and of the patients 
on hemodialysis, while  CD3+ T-cells increased only in 
the skin tissue of patients on hemodialysis. Furthermore, 
mRNA expression of podoplanin was increased in hemo-
dialysis patients compared to healthy donors. Previous 
studies in high sodium animal models, have shown that 
a high sodium diet is associated with increased sodium 
storage in the skin, increased macrophage influx and 
MCP-1 levels, inducing the production of vascular 
endothelial growth factor C (VEGF-C) by these mono-
cytes [11, 22–24]. VEGF-C mediaties lymphangiogenesis 
and several studies suggest that blocking VEGF-C has an 
increasing effect on blood pressure in relation to non-
osmotic sodium storage [25, 26]. In our study we see an 
increase of podoplanin positive lymph vessel formation 
in the dialysis group. This underlines the hypothesis that 
macrophages are mediating lymph vessel formation in 
order to contribute in maintaining an adequate sodium 
balance. As described by others (18), patients on 
hemodialysis have increased skin sodium storage and are 
able to mobilize skin sodium during hemodialysis. The 
presence and maintenance of an adequate lymphatic net-
work to accommodate this mobilization of sodium and 
water could therefore be beneficial.
Next to inflammation and lymphangiogenesis, we also 
evaluated fibrotic changes in the skin. In the skin biopsies 
of patients on hemodialysis we saw an increased mRNA 
expression of collagen I. Interestingly, Kopp et al. showed 
increased dermal sodium concentration in the fibrotic 
skin of systemic sclerosis patients [27]. We suggest that 
the differences in dermal fibrosis might be too small to 
result in differences in sodium storage.
Fibrosis emerges from the accumulation of extracel-
lular matrix. Fibroblasts play a major role by releasing 
collagens, but also reasonable amounts of proteoglycans 
and glycosaminoglycans (GAGs). Because GAGs are 
suggested to bind sodium in a non-osmotic fashion, we 
therefore took a closer look to the involvement of GAGs 
in the skin of kidney patients [28–30]. We investigated 
three groups of GAGS, namely heparin/heparan sulfate 
(HS-GAGs), chondroitin sulfate/dermatan sulfate (CS/
DS-GAG) and hyaluronic acid (HA-GAG). For CS/DS-
GAG we did not find any significant differences between 
healthy controls and kidney patients. For HS-GAG, the 
patients on hemodialysis showed increased mRNA 
expression of NDST1, an enzyme involved in the sulfa-
tion of heparan sulfate and therefore altering it’s biologi-
cal properties and possibly their sodium binding capacity. 
For HA-GAG we found a significantly lower expression 
in patients on dialysis, which might be a direct effect of 
reducing the intravascular volume [21].
Fig. 6 Diagram reflecting the number (indicated by black numbers) of associations (indicated by arrows) among clinical data, dermal sodium and 
tissue remodeling responses. Green arrows indicate positive associations, red arrows indicate negative associations
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In order to unravel the possible interplay between all 
above described phenomena, we performed association 
studies. Our data indicates that kidney disease and der-
mal sodium associates with dermal inflammation, while 
sodium homeostasis and sodium intake (reflected by 
increased plasma sodium and sodium excretion, respec-
tively) is mainly associated with lymph vessel density in 
the skin. We were not able to find a direct link between 
inflammation and lymphangiogenesis in this study. Both 
loss of kidney function, as well as an increased sodium 
excretion, is associated with decreased dermal sodium 
storage. The mechanism behind this is still unclear and 
further research is needed. While previous studies sug-
gest GAGs are involved in dermal sodium storage, we 
could not find this association in kidney patients despite 
the fact that the GAGs associated with all tissue remod-
eling phenomena [6, 7, 9, 31, 32].
We acknowledge that the present study has its limita-
tions. Firstly, the groups were very small, since we wanted 
to investigate if we were able to find any changes between 
Table 3 Correlations between clinical data, tissue remodeling responses, and dermal sodium
Correlations are performed on the Z-scores of the values of donors and preemptive patients
Variables R p-value
A. Dietary sodium intake and lymphangiogenesis
 Plasma sodium vs. podoplanin expression 0.656 0.028
 Urine sodium vs. podoplanin expression 0.709 0.022
B. Dietary sodium intake and dermal sodium
 Plasma sodium vs. dermal sodium concentration − 0.619 0.042
C. Obesity, age and proteoglycans
 Age vs. mRNA expression of HAS3 0.530 0.042
 Body weight vs. hyaluronan expression 0.503 0.047
 BMI vs. versican expression 0.562 0.024
 BMI vs. mRNA expression of CHST11 0.589 0.021
D. Proteoglycans and lymphangiogenesis
 mRNA expression of CHSY1 vs. mRNA expression of VEGF-C 0.571 0.026
 mRNA expression of CHSY1 vs. mRNA expression of podoplanin 0.546 0.035
 mRNA expression of UST vs. mRNA expression of VEGF-C 0.679 0.005
 mRNA expression of UST vs. mRNA expression of Podoplanin 0.625 0.001
 mRNA expression of HAS2 vs. mRNA expression of VEGF-C 0.757 0.001
 mRNA expression of VCAN vs. mRNA expression of podoplanin 0.600 0.018
 mRNA expression of NDST1 vs. mRNA expression of podoplanin 0.704 0.003
 mRNA expression of CHST11 vs. mRNA expression of podoplanin 0.671 0.006
E. Proteoglycans and fibrosis
 mRNA expression of VCAN vs. mRNA expression of collagen I 0.557 0.031
 mRNA expression of NDST1 vs. mRNA expression of collagen I 0.629 0.012
 mRNA expression of CHST11 vs. mRNA expression of collagen I 0.546 0.035
 mRNA expression of UST vs. mRNA expression of collagen I 0.589 0.021
 mRNA expression of HS6ST1 vs. mRNA expression of collagen I 0.514 0.050
F. Proteoglycans and inflammation
 mRNA expression of HSPE vs. CD68 expression 0.539 0.038
 mRNA expression of HAS2 vs. MCP1 expression − 0.554 0.032
 mRNA expression of UST vs. MCP1 expression − 0.621 0.013
 Heparan sulfate expression (JM403) vs. CD3 expression 0.518 0.048
G. Renal failure and inflammation
 Proteinuria vs. CD68 expression 0.730 0.007
 Proteinuria vs. MCP-1 expression 0.614 0.034
 Systolic blood pressure vs. CD68 expression 0.649 0.007
 eGFR vs. CD68 expression 0.577 0.019
H. Dermal sodium and inflammation
 Dermal sodium storage vs. mRNA expression of CCL2 − 0.582 0.023
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the groups. While both the nitrogen and the sodium 
measurements are sensitive and robust, the margin of 
errors is increasing when using smaller size skin biopsies 
since both sodium and nitrogen are calculated per mg dry 
weight. Another disadvantage of the small group sizes is 
the inability to perform multivariable linear regression or 
Cox regression analyses. Next to this, we cannot rule out 
any effect of the immunosuppressive medication that has 
been given to the kidney patients pre-OR. While kidney 
patients did show more tissue remodeling and therefore 
inflammation, the differences with the healthy group 
might have been more outspoken without immunosup-
pressive medication. Jantsch et al. have shown previously 
that antibiotics (Gentamycin) reduces sodium storage in 
the skin by in vitro [33]. In our study we used Cefazolin 
and Metronidazole in a in  vivo model, namely humans, 
who were all given prophylactic antibiotic treatment 
prior to surgery (30  min before incision). While we do 
not expect the antibiotics to have such an direct effect 
on skin sodium concentrations whitin 30 min in a physi-
ological model, in theory, we can not exclude that anti-
biotic profylaxis in all patients explains why there were 
no differences found in skin sodium concentrations. The 
same holds true for Mannitol, an osmotic diuretic, given 
maximum 30 min prior to incision. While it is theoreti-
cally possible that its diuretic properties increased uri-
nary sodium excretion, we do not expect this to have 
major effects on non-osmotic sodium binding in the skin, 
in 30 min from infusion to taking the skin biopsies right 
after incision.
The group of Titze have shown significant correlations 
between gender, age and skin sodium concentrations 
[34, 35]. In this study, we tried to age-match patients and 
donors as much as possible; however, in transplantation 
donors are selected based on HLA-type and health. We 
thus could not avoid patients to be significantly older 
compared to donors. However, Wang et al. showed a sig-
nificant increase of skin sodium concentration in elderly 
people compared to younger people [34]. Since we did 
not see a significant difference in skin sodium concentra-
tion of donors and patients, we do not expect that when 
corrected for age, patients would have lower skin sodium 
content compared to their healthy counterparts. There 
were no significant differences in age and gender between 
the patient groups themselves (preemptive and dialysis 
patients). Future studies should take into account the 
possible effects of gender and age on skin sodium con-
centration in transplant patients.
While we did not find a significant difference in skin 
sodium concentrations, we did find differences in lym-
phangiogenesis and inflammation. Different pathways 
might explain these differences and other immunologi-
cal pathways could be induced or tempered by years of 
chronic kidney disease and/or dialysis [36]. One inter-
esting alternative factor of importance in CKD, is the 
pathway of uremic inflammation. Uremic specific causes 
such as abnormalities of the phosphate-Klotho axis play a 
crucial role in CKD, having a direct effect on cellular and 
tissue function [37, 38]. Furthermore, recent studies have 
shown indoxyl sulfate (IS) to be one of the most potent 
uremic toxins involved in CKD progression, by induc-
ing inflammation and oxidative stress [39, 40]. Nakano 
et al. even showed that clinically relevant concentrations 
of indoxyl sulfate induced proinflammatory responses 
of macrophages and the influenced the roles of organic 
anion transporters and organic anion transporting poly-
peptides [39].
Next to uremic inflammation, the innate immune 
system is also known to play a crucial role in disease 
progression in CKD. While we hypothesise that gly-
cosaminoglycans are able to bind sodium non-osmot-
ically, our group has also shown that they can interact 
with complement factors [41]. Poppelaars et  al. investi-
gated the role of complement specifically in patients on 
hemodialysis. Their group showed a complement medi-
ated increased cardiovascular risk in dialysis patients 
and experimental complement inhibition revealed a 
pro-inflammatory response secondary to complement 
activation [16, 42, 43]. This might explain why the most 
profound differences in skin lymphatic vessels, GAGs 
and inflammation in our study were found in the dialy-
sis patients. Further research is warranted to investigate 
these alternative (or parallel) processes in renal trans-
plant patients.
We used unique material of chronic kidney disease 
patients; both hemodialysis patients and preemptive 
patients before transplantation and their age-matched 
healthy donors. It’s the first study investigating differ-
ences in dermal sodium concentration, sodium homeo-
stasis and tissue remodeling in these groups of ESRD 
patients. With our spectroscopy technique we were able 
to use small skin biopsies and objectively quantify the 
exact sodium concentration, finding a robust way to 
measure sodium in the skin. We performed an extensive 
analysis comparing dermal sodium concentrations, with 
tissue remodeling and different groups of GAGs, creating 
a starting point for further research.
Conclusion
In conclusion, our data suggest that there is an inter-
play among dermal sodium storage, sodium homeo-
stasis (reflected by plasma sodium) and sodium intake 
(reflected by sodium excretion), dermal tissue remod-
eling and kidney function, although the causal rela-
tionships and GAG involvement is not clear from our 
work. The exact mechanisms behind these phenomena 
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warrant further research, and underscore the remote 
dermal effects observed in kidney patients.
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